|
1
|
Galicich JH: Metastatic brain tumors.
Neurosurgery. 1. 2nd edition. Wilkins RH and Rengachary SS:
McGraw-Hill; New York, NY: pp. 807–821. 1996
|
|
2
|
Nussbaum ES, Djalilian HR, Cho KH and Hall
WA: Brain metastases. Histology, multiplicity, surgery, and
survival. Cancer. 78:1781–1788. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Patchell RA: Metastatic brain tumors.
Neurol Clin. 13:915–925. 1995.PubMed/NCBI
|
|
4
|
Johnson JD and Young B: Demographics of
brain metastasis. Neurosurg Clin North Am. 7:337–344. 1996.
|
|
5
|
Presant CA and Bartolucci AA: Prognostic
factors in metastatic malignant melanoma: The Southeastern Cancer
Study Group Experience. Cancer. 49:2192–2196. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Balch CM and Houghton AN: Diagnosis of
metastatic melanoma at distant sites. Cutaneous Melanoma. 1. 1st
edition. Balch CM, Houghton AN, Milon GW, Sober AJ and Soong SJ:
Lippincott; Philadelphia, PA: pp. 439–467. 1992
|
|
7
|
Sampson JH, Friedman AH and Seigler HF:
Demographics, treatment, and prognosis of 76 patients with
‘primary’ intracerebral melanoma. J Neurosurg. 82:A3571995.
|
|
8
|
Moon D, Maafs E, Peterson-Schaefer K, et
al: A review of 567 cases of brain metastases from malignant
melanoma. Melanoma Res. 3:401993. View Article : Google Scholar
|
|
9
|
Bhatia S, Tykodi SS and Thompson JA:
Treatment of metastatic melanoma: An overview. Oncology (Williston
Park). 23:488–496. 2009.
|
|
10
|
Fife KM, Colman MH, Stevens GN, Firth IC,
Moon D, Shannon KF, Harman R, Petersen-Schaefer K, Zacest AC,
Besser M, et al: Determinants of outcome in melanoma patients with
cerebral metastases. J Clin Oncol. 22:1293–1300. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Buchsbaum JC, Suh JH, Lee SY, Chidel MA,
Greskovich JF and Barnett GH: Survival by radiation therapy
oncology group recursive partitioning analysis class and treatment
modality in patients with brain metastases from malignant melanoma:
A retrospective study. Cancer. 94:2265–2272. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saha S, Meyer M, Krementz ET, Hoda S,
Carter RD, Muchmore J and Sutherland C: Prognostic evaluation of
intracranial metastasis in malignant melanoma. Ann Surg Oncol.
1:38–44. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sampson JH, Carter JH Jr, Friedman AH and
Seigler HF: Demographics, prognosis, and therapy in 702 patients
with brain metastases from malignant melanoma. J Neurosurg.
88:11–20. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
de la Monte SM, Moore GW and Hutchins GM:
Patterned distribution of metastases from malignant melanoma in
humans. Cancer Res. 43:3427–3433. 1983.PubMed/NCBI
|
|
15
|
Patel JK, Didolkar MS, Pickren JW and
Moore RH: Metastatic pattern of malignant melanoma. A study of 216
autopsy cases. Am J Surg. 135:807–810. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Amer MH, Al-Sarraf M, Baker LH and
Vaitkevicius VK: Malignant melanoma and central nervous system
metastases: Incidence, diagnosis, treatment and survival. Cancer.
42:660–668. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bottoni U, Clerico R, Paolino G, Ambrifi
M, Corsetti P and Calvieri S: Predictors and survival in patients
with melanoma brain metastases. Med Oncol. 30:4662013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zakrzewski J, Geraghty LN, Rose AE,
Christos PJ, Mazumdar M, Polsky D, Shapiro R, Berman R, Darvishian
F, Hernando E, et al: Clinical variables and primary tumor
characteristics predictive of the development of melanoma brain
metastases and post-brain metastases survival. Cancer.
117:1711–1720. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jakob JA, Bassett RL Jr, Ng CS, Curry JL,
Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim
KB, et al: NRAS mutation status is an independent prognostic factor
in metastatic melanoma. Cancer. 118:4014–4023. 2012. View Article : Google Scholar :
|
|
20
|
McLoughlin JM, Zager JS, Sondak VK and
Berk LB: Treatment options for limited or symptomatic metastatic
melanoma. Cancer Control. 15:239–247. 2008.PubMed/NCBI
|
|
21
|
Carella RJ, Gelber R, Hendrickson F, Berry
HC and Cooper JS: Value of radiation therapy in the management of
patients with cerebral metastases from malignant melanoma:
Radiation Therapy Oncology Group Brain Metastases Study I and II.
Cancer. 45:679–683. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hong A, Fogarty G and Izard MA: The role
of radiation therapy in the management of metastatic melanoma in
the brain. Int J Surg Oncol. 2012:2947352012.PubMed/NCBI
|
|
23
|
Jacquillat C, Khayat D, Banzet P, Weil M,
Fumoleau P, Avril MF, Namer M, Bonneterre J, Kerbrat P, Bonerandi
JJ, et al: Final report of the French multicenter phase II study of
the nitrosourea fotemustine in 153 evaluable patients with
disseminated malignant melanoma including patients with cerebral
metastases. Cancer. 66:1873–1878. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jacquillat C, Khayat D, Banzet P, Weil M,
Avril MF, Fumoleau P, Namer M, Bonneterre J, Kerbrat P, Bonerandi
JJ, et al: Chemotherapy by fotemustine in cerebral metastases of
disseminated malignant melanoma. Cancer Chemother Pharmacol.
25:263–266. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mori Y, Kondziolka D, Flickinger JC,
Kirkwood JM, Agarwala S and Lunsford LD: Stereotactic radiosurgery
for cerebral metastatic melanoma: Factors affecting local disease
control and survival. Int J Radiat Oncol Biol Phys. 42:581–589.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Overett TK and Shiu MH: Surgical treatment
of distant metastatic melanoma. Indications and results. Cancer.
56:1222–1230. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zacest AC, Besser M, Stevens G, Thompson
JF, McCarthy WH and Culjak G: Surgical management of cerebral
metastases from melanoma: Outcome in 147 patients treated at a
single institution over two decades. J Neurosurg. 96:552–558. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Houghton AN: Treatment for advanced
melanoma. Cutaneous Melanoma. 1. 1st edition. Balch CM, Houghton
AN, Milon GW, Sober AJ and Soong SJ: Lippincott; Philadelphia, PA:
pp. 468–497. 1992
|
|
29
|
Ellerhorst J, Strom E, Nardone E and
McCutcheon I: Whole brain irradiation for patients with metastatic
melanoma: A review of 87 cases. Int J Radiat Oncol Biol Phys.
49:93–97. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Morris SL, Low SH, A’Hern RP, Eisen TG,
Gore ME, Nutting CM and Harrington KJ: A prognostic index that
predicts outcome following palliative whole brain radiotherapy for
patients with metastatic malignant melanoma. Br J Cancer.
91:829–833. 2004.PubMed/NCBI
|
|
31
|
Gupta G, Robertson AG and MacKie RM:
Cerebral metastases of cutaneous melanoma. Br J Cancer. 76:256–259.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vlock DR, Kirkwood JM, Leutzinger C, Kapp
DS and Fischer JJ: High-dose fraction radiation therapy for
intracranial metastases of malignant melanoma: A comparison with
low-dose fraction therapy. Cancer. 49:2289–2294. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stridsklev IC, Hagen S and Klepp O:
Radiation therapy for brain metastases from malignant melanoma.
Acta Radiol Oncol. 23:231–235. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Madajewicz S, Karakousis C, West CR,
Caracandas J and Avellanosa AM: Malignant melanoma brain
metastases. Review of Roswell Park Memorial Institute experience.
Cancer. 53:2550–2552. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Douglas JG and Margolin K: The treatment
of brain metastases from malignant melanoma. Semin Oncol.
29:518–524. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McWilliams RR, Brown PD, Buckner JC, Link
MJ and Markovic SN: Treatment of brain metastases from melanoma.
Mayo Clin Proc. 78:1529–1536. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Eigentler TK, Figl A, Krex D, Mohr P,
Mauch C, Rass K, Bostroem A, Heese O, Koelbl O, Garbe C, et al:
Dermatologic Cooperative Oncology Group and the National
Interdisciplinary Working Group on Melanoma: Number of metastases,
serum lactate dehydrogenase level, and type of treatment are
prognostic factors in patients with brain metastases of malignant
melanoma. Cancer. 117:1697–1703. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Grob JJ, Regis J, Laurans R, Delaunay M,
Wolkenstein P, Paul K, Souteyrand P, Koeppel MC, Murraciole X,
Perragut JC, et al: Radiosurgery without whole brain radiotherapy
in melanoma brain metastases. Club de Cancérologie Cutanée. Eur J
Cancer. 34:1187–1192. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Raizer JJ, Hwu WJ, Panageas KS, Wilton A,
Baldwin DE, Bailey E, von Althann C, Lamb LA, Alvarado G, Bilsky
MH, et al: Brain and leptomeningeal metastases from cutaneous
melanoma: Survival outcomes based on clinical features. Neurooncol.
10:199–207. 2008.
|
|
40
|
Staudt M, Lasithiotakis K, Leiter U, Meier
F, Eigentler T, Bamberg M, Tatagiba M, Brossart P and Garbe C:
Determinants of survival in patients with brain metastases from
cutaneous melanoma. Br J Cancer. 102:1213–1218. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Davies MA, Liu P, McIntyre S, Kim KB,
Papadopoulos N, Hwu WJ, Hwu P and Bedikian A: Prognostic factors
for survival in melanoma patients with brain metastases. Cancer.
117:1687–1696. 2011. View Article : Google Scholar
|
|
42
|
Eisemann N, Jansen L, Holleczek B,
Waldmann A, Luttmann S, Emrich K, Hauschild A, Brenner H and
Katalinic A; GEKID Survival Working Group. Up-to-date results on
survival of patients with melanoma in Germany. Br J Dermatol.
167:606–612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wroński M and Arbit E: Surgical treatment
of brain metastases from melanoma: A retrospective study of 91
patients. J Neurosurg. 93:9–18. 2000. View Article : Google Scholar
|
|
44
|
Hofmann M, Kiecker F, Wurm R, Schlenger L,
Budach V, Sterry W and Trefzer U: Temozolomide with or without
radiotherapy in melanoma with unresectable brain metastases. J
Neurooncol. 76:59–64. 2006. View Article : Google Scholar
|
|
45
|
Mornex F, Thomas L, Mohr P, Hauschild A,
Delaunay MM, Lesimple T, Tilgen W, Bui BN, Guillot B, Ulrich J, et
al: A prospective randomized multicentre phase III trial of
fotemustine plus whole brain irradiation versus fotemustine alone
in cerebral metastases of malignant melanoma. Melanoma Res.
13:97–103. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liew DN, Kano H, Kondziolka D, Mathieu D,
Niranjan A, Flickinger JC, Kirkwood JM, Tarhini A, Moschos S and
Lunsford LD: Outcome predictors of Gamma Knife surgery for melanoma
brain metastases. Clinical article. J Neurosurg. 114:769–779. 2011.
View Article : Google Scholar
|
|
47
|
Garbe C, Hauschild A, Volkenandt M,
Schadendorf D, Stolz W, Reinhold U, Kortmann RD, Kettelhack C,
Frerich B, Keilholz U, et al: Evidence and interdisciplinary
consensus-based German guidelines: Surgical treatment and
radiotherapy of melanoma. Melanoma Res. 18:61–67. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sloan AE, Nock CJ and Einstein DB:
Diagnosis and treatment of melanoma brain metastasis: A literature
review. Cancer Control. 16:248–255. 2009.PubMed/NCBI
|
|
49
|
Steinbach J, Vordermark D and Gutzmer R:
ZNS-Metastasen - eine interdisziplinäre Herausforderung. Onkologie.
36(Suppl 4): 2–6. 2013.(In German). View Article : Google Scholar
|
|
50
|
Flanigan JC, Jilaveanu LB, Chiang VL and
Kluger HM: Advances in therapy for melanoma brain metastases. Clin
Dermatol. 31:264–281. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Miller D, Zappala V, El Hindy N,
Livingstone E, Schadendorf D, Sure U and Sandalcioglu IE:
Intracerebral metastases of malignant melanoma and their
recurrences - a clinical analysis. Clin Neurol Neurosurg.
115:1721–1728. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hanson PW, Elaimy AL, Lamoreaux WT,
Demakas JJ, Fairbanks RK, Mackay AR, Taylor B, Cooke BS, Thumma SR
and Lee CM: A concise review of the efficacy of stereotactic
radiosurgery in the management of melanoma and renal cell carcinoma
brain metastases. World J Surg Oncol. 10:1762012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fogarty GB and Hong A: Radiation therapy
for advanced and metastatic melanoma. J Surg Oncol. 109:370–375.
2014. View Article : Google Scholar
|
|
54
|
Shaw E, Scott C, Souhami L, Dinapoli R,
Kline R, Loeffler J and Farnan N: Single dose radiosurgical
treatment of recurrent previously irradiated primary brain tumors
and brain metastases: Final report of RTOG protocol 90-05. Int J
Radiat Oncol Biol Phys. 47:291–298. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Swinson BM and Friedman WA: Linear
accelerator stereotactic radiosurgery for metastatic brain tumors:
17 years of experience at the University of Florida. Neurosurgery.
62:1018–1032. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Eichler AF and Loeffler JS:
Multidisciplinary management of brain metastases. Oncologist.
12:884–898. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kocher M, Soffietti R, Abacioglu U, Villà
S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD,
Carrie C, et al: Adjuvant whole-brain radiotherapy versus
observation after radiosurgery or surgical resection of one to
three cerebral metastases: Results of the EORTC 22952–26001 study.
J Clin Oncol. 29:134–141. 2011. View Article : Google Scholar :
|
|
58
|
Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan
A, Kasper E, Eton O and Wong ET: Melanoma brain metastasis:
Overview of current management and emerging targeted therapies.
Expert Rev Neurother. 12:1207–1215. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hagen NA, Cirrincione C, Thaler HT and
DeAngelis LM: The role of radiation therapy following resection of
single brain metastasis from melanoma. Neurology. 40:158–160. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Schild SE, Behl D, Markovic SN, Brown PD,
Sande JR, Deming RL, Rowland KM Jr and Bearden JD: Brain metastases
from melanoma: Is there a role for concurrent temozolomide in
addition to whole brain radiation therapy? Am J Clin Oncol.
33:633–636. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Gibney GT, Forsyth PA and Sondak VK:
Melanoma in the brain: Biology and therapeutic options. Melanoma
Res. 22:177–183. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lyle M and Long GV: The role of systemic
therapies in the management of melanoma brain metastases. Curr Opin
Oncol. 26:222–229. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Bafaloukos D, Tsoutsos D, Fountzilas G,
Linardou H, Christodoulou C, Kalofonos HP, Briassoulis E,
Panagiotou P, Hatzichristou H and Gogas H: The effect of
temozolomide-based chemotherapy in patients with cerebral
metastases from melanoma. Melanoma Res. 14:289–294. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Schadendorf D, Hauschild A, Ugurel S,
Thoelke A, Egberts F, Kreissig M, Linse R, Trefzer U, Vogt T,
Tilgen W, et al: Dose-intensified bi-weekly temozolomide in
patients with asymptomatic brain metastases from malignant
melanoma: A phase II DeCOG/ADO study. Ann Oncol. 17:1592–1597.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Eggermont AM and Robert C: New drugs in
melanoma: it’s a whole new world. Eur J Cancer. 47:2150–2157. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Lipson EJ and Drake CG: Ipilimumab: An
anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res.
17:6958–6962. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Spagnolo F and Queirolo P: Upcoming
strategies for the treatment of metastatic melanoma. Arch Dermatol
Res. 304:177–184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Ravan MC and Matalke MS: Vemurafinib in
patients with BRAF V600E mutation-positive advanced melanoma. Clin
Ther. 34:1474–1486. 2012. View Article : Google Scholar
|
|
69
|
Keating GM: Vemurafinib: in unresectable
or metastatic melanoma. BioDrugs. 26:325–334. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Palathinkal DM, Sharma TR and Koon HB:
Current systemic therapies for melanoma. Dermatol Surg. 40:948–963.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Margolin K, Atkins B, Thompson A, Ernstoff
S, Weber J, Flaherty L, Clark I, Weiss G, Sosman J, Smith W II, et
al: Temozolomide and whole brain irradiation in melanoma metastatic
to the brain: A phase II trial of the Cytokine Working Group. J
Cancer Res Clin Oncol. 128:214–218. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Atkins MB, Sosman JA, Agarwala S, Logan T,
Clark JI, Ernstoff MS, Lawson D, Dutcher JP, Weiss G, Curti B, et
al: Temozolomide, thalidomide, and whole brain radiation therapy
for patients with brain metastasis from metastatic melanoma: A
phase II Cytokine Working Group study. Cancer. 113:2139–2145. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Hartford AC, Paravati AJ, Spire WJ, Li Z,
Jarvis LA, Fadul CE, Rhodes CH, Erkmen K, Friedman J, Gladstone DJ,
et al: Postoperative stereotactic radiosurgery without whole-brain
radiation therapy for brain metastases: Potential role of
preoperative tumor size. Int J Radiat Oncol Biol Phys. 85:650–655.
2013. View Article : Google Scholar
|
|
74
|
Kelly PJ, Lin YB, Yu AY, Alexander BM,
Hacker F, Marcus KJ and Weiss SE: Stereotactic irradiation of the
postoperative resection cavity for brain metastasis: A frameless
linear accelerator-based case series and review of the technique.
Int J Radiat Oncol Biol Phys. 82:95–101. 2012. View Article : Google Scholar
|
|
75
|
Jagannathan J, Yen CP, Ray DK, Schlesinger
D, Oskouian RJ, Pouratian N, Shaffrey ME, Larner J and Sheehan JP:
Gamma Knife radiosurgery to the surgical cavity following resection
of brain metastases. J Neurosurg. 111:431–438. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Foletto MC and Haas SE: Cutaneous
melanoma: New advances in treatment. An Bras Dermatol. 89:301–310.
2014. View Article : Google Scholar : PubMed/NCBI
|
